778.36

3.35% 25.24

After Hours: 782.54 4.18 +0.54%

Regeneron Pharmaceuticals Inc (REGN)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Regeneron Pharmaceuticals Inc stock is traded at $778.36, with a volume of 877.73K. It is up +3.35% in the last 24 hours and down -1.94% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Previous Close:

$753.12

Open:

$758.16

24h Volume:

877.73K

Relative Volume:

1.31

Market Cap:

$80.14B

Revenue:

$14.92B

Net Income/Loss:

$4.42B

P/E Ratio:

18.96

EPS:

41.0422

Net Cash Flow:

$3.79B

1W Performance:

+4.88%

1M Performance:

-1.94%

6M Performance:

+3.02%

1Y Performance:

+35.93%

1-Day Range:

$755.21

$781.84

1-Week Range:

$732.83

$781.84

52-Week Range:

$553.87

$859.34

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name

Regeneron Pharmaceuticals Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(914) 847-7000

Address

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Employee

15,410

Twitter

@regeneron

Next Earnings Date

2026-10-30

Latest SEC Filings

REGN's Discussions on Twitter

Compare REGN vs VRTX, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REGN Regeneron Pharmaceuticals Inc	778.36	80.14B	14.92B	4.42B	3.79B	41.04
VRTX Vertex Pharmaceuticals Inc	498.50	126.35B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	226.30	90.35B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	818.30	51.46B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	193.52	41.48B	742.00K	-1.37B	-1.07B	-7.0731

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-01-26	Upgrade	Argus	Hold → Buy
May-18-26	Downgrade	Citigroup	Buy → Neutral
May-18-26	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-31-26	Resumed	Piper Sandler	Overweight
Mar-06-26	Initiated	Barclays	Overweight
Jan-07-26	Upgrade	BofA Securities	Underperform → Buy
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-24-25	Initiated	HSBC Securities	Buy
Nov-24-25	Resumed	Truist	Buy
Nov-13-25	Initiated	Scotiabank	Sector Perform
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight
May-14-25	Upgrade	Citigroup	Neutral → Buy
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform
Jan-16-25	Downgrade	UBS	Buy → Neutral
Dec-10-24	Resumed	BofA Securities	Underperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-14-24	Initiated	Citigroup	Neutral
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-12-24	Initiated	Bernstein	Outperform
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-21-23	Reiterated	Oppenheimer	Perform
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-24-23	Upgrade	Jefferies	Hold → Buy
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line
Sep-09-22	Upgrade	Jefferies	Underperform → Hold
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-06-22	Initiated	Jefferies	Underperform
May-23-22	Initiated	SVB Leerink	Outperform
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-15-21	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-09-21	Resumed	Wells Fargo	Overweight
Dec-07-21	Resumed	Cowen	Market Perform
Dec-06-21	Initiated	Goldman	Buy
Nov-19-21	Resumed	BMO Capital Markets	Outperform
Nov-05-21	Downgrade	The Benchmark Company	Buy → Hold
Jun-29-21	Initiated	H.C. Wainwright	Buy
Jan-25-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-13-21	Upgrade	The Benchmark Company	Hold → Buy
Jan-08-21	Upgrade	Citigroup	Neutral → Buy
Oct-05-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-20-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-09-20	Upgrade	SunTrust	Hold → Buy
May-26-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Apr-28-20	Downgrade	Citigroup	Buy → Neutral
Apr-17-20	Upgrade	The Benchmark Company	Hold → Buy
Apr-08-20	Initiated	The Benchmark Company	Hold
Mar-31-20	Initiated	Wolfe Research	Peer Perform
Feb-27-20	Initiated	Barclays	Overweight
Feb-26-20	Upgrade	Canaccord Genuity	Hold → Buy
Feb-26-20	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-25-20	Upgrade	Jefferies	Hold → Buy
Feb-11-20	Upgrade	Argus	Hold → Buy
Dec-24-19	Initiated	Raymond James	Mkt Perform
Dec-16-19	Downgrade	Evercore ISI	Outperform → In-line
Dec-13-19	Upgrade	Credit Suisse	Neutral → Outperform
Nov-12-19	Initiated	SunTrust	Hold
Nov-07-19	Upgrade	Citigroup	Neutral → Buy
Oct-17-19	Resumed	BofA/Merrill	Neutral
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy

View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

Oct 14, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research

Oct 14, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 14, 2026

Oct 13, 2026

RBC raises target for Regeneron stock to USD 810.00 - ad-hoc-news.de

Oct 13, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 13, 2026

Regeneron reports 84-week Phase III data for Pasatru in adult FOP - Yahoo Finance

Oct 13, 2026

Regeneron reports Pasatru data and Citi holds Regeneron stock - ad-hoc-news.de

Oct 13, 2026

Regeneron presents new long-term data for Pasatru - The Pharma Letter

Oct 13, 2026

Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95 - ad-hoc-news.de

Oct 13, 2026

Oct 12, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 12, 2026

Regeneron’s New Drug Halts Rogue Bone Growth EffectivelyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga

Oct 12, 2026

Regeneron Reports Sustained 84-Week Efficacy Data for Pasatru in Adults With FOP - Quiver Quantitative

Oct 12, 2026

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Oct 12, 2026

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month - Stocktwits

Oct 12, 2026

Oct 11, 2026

Should Alliance Expansion Require Action From Regeneron (REGN) Investors? - Simply Wall Street

Oct 11, 2026